Phone : 1-415-349-0054 Toll Free : 1-888-202-9519 Email : sales @ radiantinsights . com Web : http :// www . radiantinsights . com /
Frontier Pharma -Hepatitis C Market Research Report 2025
Hepatitis C is a blood-borne viral infection characterized by chronic inflammation of the liver . Although patients may be asymptomatic for a number of years or decades , chronic HCV infection can lead to liver fibrosis ( formation of scar tissue ) and ultimately liver cirrhosis , in which permanent fibrotic scar tissue replaces healthy liver cells . In severe cases , cirrhosis may lead to liver failure and death . In addition , hepatitis C patients are at an increased risk of developing liver cancer .
Hepatitis C has a high global prevalence , with the number of people living with the disease estimated at 130-170 million worldwide . Before the arrival of direct-acting antivirals ( DAA ) in 2011 , the gold-standard of hepatitis C therapy consisted of the host-targeting drugs pegylated interferonα and ribavirin , which were associated with significant side effects .
Browse Full Research Report @: http :// www . radiantinsights . com / research / frontier-pharmahepatitis-c
Despite the entry of these new therapies , there is a subgroup of patients that do not respond to current treatments , or relapse . In addition , HCV resistance to DAAs may also be a cause for concern , as the development of selection pressure by the host immune system in combination with DAA therapy may lead to outgrowth of resistant viruses . As such , the rationale for investment in first-in-class innovation remains strong .
Reason to Buy :
� Appreciate the current clinical and commercial landscapes by considering disease pathogenesis , etiology , epidemiology , symptoms , co-morbidities and complications , and treatment options and algorithms .
� Visualize the composition of the hepatitis C market in terms of dominant classes of therapies . Key unmet needs are identified to allow a competitive understanding of gaps in the market .
� Recognize innovative pipeline trends by analysing therapies by stage of development , molecule type and molecular target .
� Assess the therapeutic potential of first-in-class targets . Using a proprietary matrix tailored to hepatitis C , all first-in-class targets in the hepatitis C pipeline have been assessed and ranked according to clinical potential . Promising early-stage targets have been further reviewed in greater detail .
� Consider first-in-class pipeline products with no prior involvement in licensing and codevelopment deals that may represent potential investment opportunities .
https
:// www . facebook . com / RadiantInsights
https :// www . linkedin . com / company / radiant-insights https :// twitter . com / radiantinsights
https :// plus . google . com /+ Radiantinsights